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Congenital factor XIII (FXIII) deficiency is a rare coagulopathy with the 
highest incidence in Iran. Iranian patients with FXIII deficiency (FXIIID) 
presented high rate of bleeding episodes, some of them are major cause of 
disability and mortality among these patients. Hemarthrosis and intracranial 
hemorrhage (ICH) can affect activity and social productivity of patients. 
ICH, recurrent miscarriage and umbilical cord bleeding are the major cause 
of mortality. Hematoma, and prolonged menstrual bleeding as well as post-
surgical bleeding are other significant bleeding in Iranian patients with 
FXIIID. Present of severe life threatening bleeding episodes and other 
notable bleedings, can significantly reduce working activities and social 
productivities of patients. Although Iranian patients with FXIIID, 
experienced significant diseases related complications, early diagnosis 
accompany by appropriate therapeutic regimes can prevent most of these 
problems. 
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Introduction 
Coagulation factor XIII (FXIII) is a fibrin-stabilizing 
transglutaminase which strengthens fibrin clot 
mechanically by cross-linking fibrin chains. In 
addition, it protects newly formed fibrin from the 
activated fibrinolytic system by binding 2-plasmin 
inhibitor to the fibrin meshwork (1). Congenital FXIII 
deficiency (FXIIID) is an extremely rare but 
significant bleeding disorder with a prevalence of 1 
per 2 million in the general population (2, 3). Patients 
with severe deficiency, present high rate of life 
threatening bleeding, including umbilical cord 
bleeding (UCB), recurrent pregnancy loss and 
intracranial hemorrhage (ICH) (4, 5). ICH is the 
major cause of death among these patients and it is 
more common in FXIIID in comparison to other rare 
bleeding disorders (RBDs) (6). UCB is the most 
common bleeding lead to diagnosis of disorder. This 
bleeding is also common in fibrinogen disorders (7). 
Diagnosis of the FXIIID is commonly performed 
based on clinical presentation, family history as well 
as appropriate laboratory tests (8, 9). Clot solubility 
test is a quantitative and low sensitive diagnostic test 
which is most commonly used for detection of 
FXIIID. This diagnostic test is not further 
recommended by experts for diagnosis of disorder. 
Howevere,  a functional assay is recommended as 
first screening test (3, 10, 11). Management of the 
disorder is made traditionally by fresh frozen plasma, 
cryoprecipitate and today by FXIII concentrate 
(Fibrogammin P) (1, 3). 
Factor XIII Deficiency in Iran 
Since this disorder is transmitted in autosomal 
recessive manner of inheritance, it is more common in  
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areas with high rate of consanguineous marriages 
(12). Iran as a Mideast country with high rate of 
consanguineous marriage has high prevalence of 
FXIIID. With 483 patients, Iran has about one fourth 
of world patients with FXIIID (2). This high spread of 
disorder leads to high rate of morbidity and mortality 
among Iranian patients. The main cause for this high 
rate of morbidity and mortality among Iranian 
patients is low equipped coagulation laboratory and 
therefore nonspecific diagnostic tests in areas with 
high prevalence of FXIIID (8). In addition, littleto 
low diagnostic tools, long distance with health care 
centers and low economic situation of affected 
families are other factors lead to this high rate of 
morbidity and mortality. In the recent years, the 
number of affected patients continuously is increased 
(2, 8). In southeast of Iran, as hot spot of disease, the 
number of affected patients is increased from 46 in 
2004 to 205, 352, 410 in 2011, 2015 and 2016 
respectively. The numbers of affected patients in Iran, 
exception of southeast areas, were 121 and 131 in 
2015 and 2016, respectively (Figure 1) (2). 11 
different mutations are observed in 366 Iranian 
patients with FXIIID. Trp187Arg, observed only in 
Iran, is the leading cause of FXIIID in this country 
(13). 
Burden of factor XIII deficiency in Iran 
The high risk of severe bleeds and ICH in 
patients with FXIIID is likely to result in a high level 
of physical, psychological and financial burden (5). 
Although the number of patients was significantly 
increased, but clot solubility test remains as the only 
diagnostic test for FXIIID. Clot solubility test has low 
sensitivity and it is just positive in severe FXIIID 
(10). Among patients in southeast of Iran, Khash city 
has the highest incidence of disease where there is not 
any comprehensive coagulation laboratory. 
Consequently, patients had to travel to Zahedan as 
provincial center, even for early diagnosis of disorder 
with clot solubility test. Since considerable numbers 
of patients in Khash are resident of rural areas with 
low economic situation, this travel is expensive for 
them. Moreover, the only hemophilia center of Sistan 
and Baluchestan province is located in Zahedan city. 
In fact, all diagnostic and health care facilities are 
located in the Zahedan as provincial center. This issue 
is a problem for early and timely diagnosis of disorder 
and can lead to high rate of morbidity and mortality 
among these patients (4, 8).  
UCB, the most common clinical manifestation, 
which has reported in 80% of Iranian patients, occurs 
in early of life. Although this kind of bleeding is a 
major life threating bleeding, it easily could be 
managed with early diagnosis of FXIIID. Overall, it is 
a medical emergency that requires timely medical 
interventions (2, 8). In a study on 317 patients with 
FXIIID, 221 (69.7%) UCB was observed, that led to 
death in 21 neonates (~10%) (Figure 2) (8, 14).  
In addition, to UCB, ICH is another risk factor 
for patients with FXIIID, which leads to high rate of 
mortality and related complications. Occurrence of 
CNS bleeding (CNSB) in pediatric patients with 
FXIIID causes different types of neurological 
complications including behavioral and 
developmental disorders as well as hemiplegia and 
aphasia (3, 15). The kind of CNSB in 95 patients with 
FXIIID was determined; in 91 cases (95.8%) and 4 
cases (4.2%) were ICH and extracranial hemorrhage 
(ECH), respectively. According to a report on age in 
at the time of CNSB, about one third of patients 
experienced CNSB in the first two years of life. A 
number of these patients with FXIIID, experienced 
CNSB following minor trauma but most of them 
experienced this complication spontaneously. In 
Sistan and Baluchestan province, with high rate of 
FXIIID, different types of complications reported 
which not observed in other areas of the world (8). 
Each of these complications required an urgent 
medical decision. As we have observed, one of the 
major complication among neonates with FXIIID, 
following to a normal vaginal delivery is ICH. 
Neonates with FXIIID following the delivery and the 
 
Figure 1. Prevalence of factor XIII deficiency in Iran. 
Dorgalaleh et al.                                                                                              Burden of Congenital Factor XIII Deficiency in Iran 
 Journal of Cellular & Molecular Anesthesia (JCMA) 
144 
stress of passing through delivery canal experience 
CNSB. In fact, in this traditional society, most of 
mothers prefer to deliver their child in a normal 
vaginal delivery. To deal with this problem a prenatal 
diagnosis (PND) program was established in this area 
and parents were assessed for Trp187Arg mutation of 
FXIII-A gene (4, 16). This was the only reported 
disease resulted from mutation in the gene of FXIII in 
this area. Almost all of patients in southeast of Iran 
were homozygote for this mutation (13). Out of 317 
patients, about half of them (~46%) were experienced 
ICH. About two-third (~73%) of them experienced 
neurological complications and one-third were died 
(Figure 2) (8). Some of these neurological 
complications are severe and disruptive of routine life 
style of the patients. Other CNSB related 
complications can significantly reduce social 
communications and activities of patients. Since ICH 
can occurred spontaneously of post trauma, patients 
with severe FXIIID, should be cautious about their 
routine activities. In fact, ICH is a major obstacle for 
normal social activity and major cause of disability in 
patients with FXIIID (2).  
Other significant complication of FXIIID is 
miscarriage. Some studies reported that without 
appropriate prophylaxis regimes, there is not any 
woman with severe FXIIID who has a successful 
delivery. Therefore, with a suitable replacement 
therapy, almost all women with this complication, can 
have a successfully delivery. Recurrent miscarriage is 
a very important FXIIID related complications and 
has high rate of mortality (16). Among 24 women 
with FXIIID, a total of 62 miscarriages were observed 
which revealed nearly three times abortions for each 
mother (Figure 2) (8). In addition to morbidity and 
mortality effects of miscarriage and recurrent 
miscarriages, it has emotional effects on families with 
FXIIID too, especially on affected mother. 
Sometimes, this severe complication of FXIIID has 
crucial social consequences in affected families (16).  
In addition to these complications, other 
bleedings among  patients with FXIIID can affect 
their activity and social productivity. Hematoma, 
hemarthrosis, prolonged menstrual bleeding, muscle 
and subcutaneous soft tissues hemorrhages, as well as 
post-surgical bleeding are other bleeding symptoms 
among these patients, which could affect their 
physical health and optimal activity. With timely 
diagnosis of FXIIID and appropriate therapeutic 
regimes, most of these bleeding and related morbidity 
 
Figure 2. This flow chart illustrates prevalence of mortality in factor XIII deficiency. There are three life threating 
complications that lead to mortality in FXIIID: 1.CNS bleeding 2.misscarriage 3.umbilical cord bleeding. 
 * 73% of patients with CNS (central nervouse systeme)  bleeding show neurological complications instead of death. 
**UD: undetermined. 
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and mortality can be prevented (4, 9). 
Conclusion 
Congenital FXIIID is a rare but very severe 
bleeding disorder acompnied by high rate of life 
threatening bleeds. ICH, recurrent miscarriage and 
umbilical cord bleeding are the main cause of 
morbidity and mortality among these patients that 
imposed high rate of disease burden to health care 
system. Although the disorder is accompanied by high 
rate of life threteaning bleeds, timely diagnosis and 
appropriate management of disorder can be 
eliminated or significantly decreased. 
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